On September 8, 2021 GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE protein biologic technology platform, reported that Anthony Cataldo, Chairman & CEO, Dr. Greg Berk, President of R&D and Chief Medical Officer, and Dr. Jeff Miller, Consulting Chief Scientific Officer will be presenting and hosting one-on-one meetings at the upcoming H.C. Wainwright 23rd Annual Global Healthcare Conference and the Baird Global Healthcare Conference (Press release, GT Biopharma, SEP 8, 2021, View Source [SID1234587390]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the presentations are as follows:

H.C. Wainwright 23rd Annual Global Healthcare Conference

Date: September 13, 2021
Pre-recorded Corporate Presentation Release Time: 7:00 A.M. ET
Webcast Participation: View Source

Additionally, the management team will participate in the following live panel presentation: "Novel Therapeutic Approaches to NK Therapy in Cancer" at 1:00P.M. ET

Baird Global Healthcare Conference

Date: September 15, 2021
Time: 8:30 A.M. ET
Registration: By invitation only

If you are interested in participating in either of the conferences or to schedule a one-on-one meeting with the management team, please contact your respective representative with each conference organizer.